title: Rates of major complications during neoadjuvant and adjuvant chemotherapy for early breast cancer: An off study population.
abstract: OBJECTIVE
  To determine the incidence and risk factors for thromboembolic events (TE) and febrile neutropenia (FN) in patients receiving systemic chemotherapy for early breast cancer (EBC).
  
  
  METHODS
  325 patients received FEC75, FEC100-T or ECaP for EBC in 2013.
  
  
  RESULTS
  TE occurred in 7.4% and FN in 19.1% of patients. Risk factors for TE were: central venous catheter (p = 0.011). Risk factors for FN were: FEC100-T treatment versus FEC75and ECaP (p ≤ 0.001); lower pre-treatment neutrophil count (p = 0.009) and poorer performance status (p = 0.012). Two patients died from treatment-related toxicities.
  
  
  CONCLUSIONS
  In real-world experience, the majority of patients completed adequate treatment, despite significant complications.
authors: Breast Unit, The Royal Marsden NHS Foundation Trust, London, United Kingdom.
authors: S
authors: S
authors: Redana
authors: Breast Unit, The Royal Marsden NHS Foundation Trust, London, United Kingdom; Institute of Cancer Research, London, United Kingdom.
authors: A
authors: A
authors: Sharp
authors: Breast Unit, The Royal Marsden NHS Foundation Trust, London, United Kingdom; Institute of Cancer Research, London, United Kingdom.
authors: H
authors: H
authors: Lote
authors: Research and Development Department, The Royal Marsden NHS Foundation Trust, London, United Kingdom.
authors: K
authors: K
authors: Mohammed
authors: Breast Unit, The Royal Marsden NHS Foundation Trust, London, United Kingdom.
authors: E
authors: E
authors: Papadimitraki
authors: Breast Unit, The Royal Marsden NHS Foundation Trust, London, United Kingdom.
authors: M
authors: M
authors: Capelan
authors: Breast Unit, The Royal Marsden NHS Foundation Trust, London, United Kingdom. Electronic address: alistair.ring@rmh.nhs.uk.
authors: A
authors: A
authors: Ring
mesh_terms: D054058:Acute Coronary Syndrome / Q000453:epidemiology*; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D018270:Carcinoma, Ductal, Breast / Q000188:drug therapy* / Q000473:pathology; D018275:Carcinoma, Lobular / Q000188:drug therapy* / Q000473:pathology; D017024:Chemotherapy, Adjuvant / Q000009:adverse effects; D064146:Chemotherapy-Induced Febrile Neutropenia / Q000453:epidemiology*; D003520:Cyclophosphamide / Q000008:administration & dosage; D000077143:Docetaxel; D004305:Dose-Response Relationship, Drug; D015251:Epirubicin / Q000008:administration & dosage; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D015994:Incidence; D008408:Mastectomy; D015412:Mastectomy, Segmental; D008875:Middle Aged; D020360:Neoadjuvant Therapy / Q000009:adverse effects; D009367:Neoplasm Staging; D017239:Paclitaxel / Q000008:administration & dosage; D011655:Pulmonary Embolism / Q000453:epidemiology*; D012189:Retrospective Studies; D012307:Risk Factors; D021701:Sentinel Lymph Node Biopsy; D020521:Stroke / Q000453:epidemiology*; D043823:Taxoids / Q000008:administration & dosage; D013923:Thromboembolism / Q000453:epidemiology; D020246:Venous Thrombosis / Q000453:epidemiology*
chemical_list: D043823:Taxoids; D000077143:Docetaxel; D015251:Epirubicin; D003520:Cyclophosphamide; D017239:Paclitaxel; D005472:Fluorouracil
keywords: Adjuvant chemotherapy; Early breast cancer (EBC); Febrile neutropenia; Neoadjuvant chemotherapy; Thromboembolic events; Treatment related toxicity